Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 17/20 | 0.80 |
| ▸ | EDNRB | P24530 | 16/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | TSPO | P30536 | 1/20 | 0.74 |
| ▸ | DRD3 | P35462 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31266904 | 1.00 | EDNRA (0.80) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL5097931 | 0.94 | EDNRB (0.72) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL5500351 | 0.90 | EDNRA (0.86) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL9891388 | 0.89 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| Aprocitentan SCHEMBL30439551 | 0.89 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| Aprocitentan SCHEMBL3646065 | 0.89 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL3650930 | 0.89 | EDNRA (0.80) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL17582648 | 0.87 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL5494210 | 0.87 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL8802029 | 0.86 | EDNRB (0.84) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323465-B2 | Alkansulfonamides as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-01-29 | — | — | US | claimed |
| EP-1465875-B1 | NOVEL ALKANSULFONAMIDES AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-12-19 | — | — | EP | claimed |
| US-20050085639-A1 | Novel alkansulfonamides as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-04-21 | — | — | US | claimed |
| EP-1465875-A1 | NOVEL ALKANSULFONAMIDES AS ENDOTHELIN ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2004-10-13 | — | — | EP | claimed |
| WO-2003055863-A1 | NOVEL ALKANSULFONAMIDES AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-07-10 | — | — | WO | claimed |
| US-7323465-B2 | Alkansulfonamides as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-01-29 | — | — | US | disclosed |
| EP-1465875-B1 | NOVEL ALKANSULFONAMIDES AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20050085639-A1 | Novel alkansulfonamides as endothelin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-04-21 | — | — | US | disclosed |
| EP-1465875-A1 | NOVEL ALKANSULFONAMIDES AS ENDOTHELIN ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003055863-A1 | NOVEL ALKANSULFONAMIDES AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085639-A1 | Novel alkansulfonamides as endothelin antagonists | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885SLC6A2 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.